Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 12, 2005, Pages 4780-4787

  Yoo, Min Heui ^a   Hyun, Hyae Jung ^a   Koh, Jae Young ^a   Yoon, Young Hee ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE C BETA; PROTEIN KINASE C BETAII; RILUZOLE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; AMINO ACID RECEPTOR BLOCKING AGENT; PROTEIN KINASE C; VASCULOTROPIN A;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DEXTRAN FLUORESCENCE RETINA ANGIOGRAPHY; DRUG APPROVAL; ENDOTHELIUM CELL; FOOD AND DRUG ADMINISTRATION; HYPEROXIA; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEIN PHOSPHORYLATION; RAT; RETINA ANGIOGRAPHY; RETROLENTAL FIBROPLASIA; ADOLESCENT; ANIMAL; CATTLE; CULTURE TECHNIQUE; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; METABOLISM; NEWBORN; PATHOLOGY; PREGNANCY; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; SPRAGUE DAWLEY RAT; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ADOLESCENT; ANIMALS; ANIMALS, NEWBORN; CATTLE; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; HYPEROXIA; INFANT, NEWBORN; PREGNANCY; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; RILUZOLE; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644814322     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0376     Document Type: Article

References (48)

1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
2. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-10461.
3. Keck PJ, Hauser SD, Krivi G. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309-1312.
4. Beauchamp MH, Marrache AM, Hou X, et al. Platelet-activating factor in vasoobliteration of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2002;43:3327-3337.
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Medicine. 2003;9:669-676.
6. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
7. McLeod DS, Taomoto M, Cao J, Zhu Z, Witte L, Lutty GA. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2002;43:474-482.
8. DeVries C, Escobeido J, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255:989-991.
9. Millauer B, Witzigmann-Voos S, Schnuerch H. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72:835-846.
10. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
11. Madan A. Angiogenesis and antiangiogenesis in the neonate relevance to retinopathy of prematurity. NeoReviews. 2003;4:e356-363.
12. Pierce EA, Foley ED, Smith LEH. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996;114:1219-1228.
13. Stone J, Chan-Ling T, Pe'er J, Itin A, Gnessin H, Keshet E. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1996;37:290-299.
14. Donahue ML, Phelps DL, Watkins RH, LoMonaco MB, Horowitz S. Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen-induced retinopathy. Curr Eye Res. 1996;15:175-184.
15. Robbins SG, Rajaratnam VS, Penn JS. Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptors flt-1 and flk-1 in the oxygen-injured rat retina. Growth Factors. 1998;16:1-9.
16. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
17. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C. its isoforms, and endothelial cell growth. J Clin Invest. 1996;98:2018-2026.
18. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999;18:2221-2230.
19. Daviet I, Herbert JM, Maffrand JP. Tumor-promoting phorbol esters stimulate bovine cerebral cortex capillary endothelial cell growth in vitro. Biochem Biophys Res Commun. 1989;158:584-589.
20. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-866.
21. Frank RN. Potential new medical therapies for diabetic retinopathy. Protein kinase C inhibitor. Am J Ophthalmol. 2002;133:693-698.
22. Koh JY, Wie MB, Gwag BJ, et al. Staurosporine-induced neuronal apoptosis. Exp Neurol. 1995;135:153-159.
23. Kabir J, Lobo M, Zachary I. Staurosporine induces endothelial cell apoptosis via focal adhesion kinase dephosphorylation and focal adhesion disassembly independent of focal adhesion kinase proteolysis. Biochem J. 2002;367:145-155.
24. Nakamura KK, Hamada Y, Nakayama M, et al. A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes. 1999;48:2090-2095.
25. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996;272:699-700.
26. Kim H, Sasaki T, Maeda K, Koya D, Kashiwagi A, Yasuda H. Protein kinase Cβ selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons. Diabetes. 2003;52:2102-2109.
27. Meininger V, Lacomblez L, Salachas F. What has changed with riluzole? J Neurol. 2000;247:VI19-VI22.
28. Doble A. Effects of riluzole in glutamatergic neurotransmission in the mammalian central nervous system, and other pharmacological effects. Rev Contemp Pharmacother. 1997;8:213-225.
29. Schiefer J, Landwehrmeyer GB, Lüesse HG, et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Movement Disorders. 2002;17:748-757.
30. Ettaiche M, Fillacier K, Widmann C, Heurteaux C, Lazdunski M. Riluzole improves functional recovery after ischemia in the rat retina. Invest Ophthalmol Vis Sci. 1999;40:729-736.
31. Urenjak J, Obrenovitch TP. Pharmaacologucal modulation of sodium channels by riluzole: an alternative to antiexcitotoxic actions. Rev Contemp Phamacother. 1997;8:237-346.
32. Hebert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol. 1994;45:1055-1060.
33. Noh KM, Hwang JY, Shin HC, Koh JY. A novel neuroprotective mechanism of riluzole: Direct inhibition of protein kinase C. Neurobiol Dis. 2000;7:375-383.
34. Hoffmann S, Spee C, Murata T, Cui JZ, Ryan SJ, Hinton DR. Rapid isolation of choriocapillary endothelial cells by Lycopersicon esculentum-coated Dynabeads. Graefes Arch Clin Exp Ophthalmol. 1998;236:779-784.
35. Devaraj S, Venugopal SK, Singh U, Jialal I. Hyperglycemia induces monocytic release of interlukin-6 via induction of protein kinase C-α and β. Diabetes. 2005;54:85-91.
36. Higgins RD, Yu K, Sanders RJ, Nandgaonkar BN, Rotschild T, Rifkin DB. Diltiazem reduces retinal neovascularization in a mouse model of oxygen induced retinopathy. Cur Eye Res. 1999;18:20-27.
37. Phelps DL, Rosenbaum AL. Effects of marginal hypoxemia on recovery from oxygen-induced retinopathy in the kitten model. Pediatrics. 1984;73:1-6.
38. Phelps DL. Retinopathy of prematurity: an estimate of vision loss in the United States-1979. Pediatrics. 1981;67:924-925.
39. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
40. International Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity (special article). Pediatrics. 1984;74:127-133.
41. Higgins RD, Yan Y, Geng Y, Zasloff M, Williams JI. Regression of retinopathy by squalamine in a mouse model. Pediatr Res. 2004;56:144-149.
42. Miller RG, Bouchard JP, Duquette P, et al. Clinical trials of riluzole in patients with ALS/Riluzole Study Group-II. Neurology. 1996;47:S86-90.
43. Cheramy A, Barbeito L, Godeheu G, Glowinski J. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett. 1992;147:209-212.
44. Jehle T, Bauer J, Blauth E, et al. Effects of riluzole on electrically evoked neurotransmitter release. Br J Pharmacol. 2000;130:1227-1234.
45. Zona C, Siniscalchi A, Mercuri NB, Bernardi G. Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience. 1998;85:931-938.
46. Huang CS, Song JH, Nagata K, Yeh JZ, Narahashi T. Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal ganglion neurons. J Pharm Exp Ther. 1997;282:1280-1290.
47. Groeneveld GJ, Van Kan HJM, Kalmijn S, et al. Riluzole serum concentrations in patients with ALS. Neurology. 2003;61:1141-1143.
48. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473-1480.